In this article

本文中

NOVO.B-DK

NOVO.B-DK

LLY

礼来公司

Follow your favorite stocks

关注你喜爱的股票

CREATE FREE ACCOUNT

创建免费账户

A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk.

组合图像显示了礼来公司的减肥药Zepbound的注射笔，以及诺和诺德公司生产的Wegovy药盒。

Reuters

路透社

President

总统

Donald Trump

唐纳德·特朗普

on Friday dropped a

周五放弃了

Biden administration proposal

拜登政府提案

to have Medicare cover obesity drugs, including popular but costly GLP-1 treatments such as

为了让 Medicare 覆盖肥胖症药物，包括受欢迎但昂贵的 GLP-1 治疗药物，如

Novo Nordisk

诺和诺德

's Wegovy and

韦哥维和

Eli Lilly

礼来公司

's Zepbound.

泽普邦德。

But the Centers for Medicare and Medicaid Services said it may reconsider coverage of those drugs in the future, according to a

但医疗保险和医疗补助服务中心表示，根据一则消息，未来可能会重新考虑对这些药物的覆盖。

fact sheet

事实清单

on the rule.

关于规则。

The proposal would have given millions more Americans access to those drugs, but would have cost the government billions. Many health plans, including Medicare, don't currently cover weight loss treatments, and some patients simply can't afford their hefty price tags before insurance.

该提案本可以让数百万美国人更容易获得这些药物，但代价是政府将花费数十亿美元。包括 Medicare 在内，许多健康计划目前并不涵盖减肥治疗，而一些患者在保险未覆盖的情况下，根本负担不起这些药物高昂的费用。

Wegovy and Zepbound both cost roughly $1,000 before insurance and other rebates. Allowing Medicare to cover those drugs and other weight loss medications could

Wegovy 和 Zepbound 在保险和其他折扣之前的价格都大约为 1000 美元。允许 Medicare 覆盖这些药物以及其他减肥药物可能会

cost $35 billion

花费350亿美元

over nine years, a congressional analysis found.

超过九年，国会分析发现。

Under the Biden administration's proposal, only those who are considered obese — someone who has a body mass index of 30 or higher — would qualify for coverage. Some people may already get coverage of the drugs through Medicare or Medicaid if they have diabetes or are at risk for stroke or heart disease..

根据拜登政府的提案，只有被认为是肥胖者——即身体质量指数为30或更高的人——才有资格获得保险覆盖。如果有些人患有糖尿病或有中风或心脏病的风险，他们可能已经通过联邦医疗保险或医疗补助计划获得了这些药物的保险覆盖。

The rule wasn't finalized before Trump took office.

特朗普上任前，该规定尚未最终确定。

Novo Nordisk and Eli Lilly did not immediately respond to requests for comment.

诺和诺德和礼来公司没有立即回应置评请求。

Shares of Lilly fell more than 2% in extended trading, while Novo Nordisk's stock dropped more than 1%.

礼来公司的股价在盘后交易中下跌了2%以上，而诺和诺德的股票下跌了1%以上。